Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 9,999 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: TARGET Clear all

Conditions: Glioblastoma, MGMT-Unmethylated Glioblastoma
Interventions: Microtubule-Targeted Agent BAL101553, Radiation Therapy; Drug · Radiation
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 8
States / cities: Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 5 more

Conditions: Overweight and Obesity, PreDiabetes, Type 2 Diabetes, Cardiovascular Risk Factor
Interventions: Body Fat Distribution Imaging Report, Basic Weight Information, Patient Provided, Physician Provided; Diagnostic Test · Behavioral
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 35 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Healthy Volunteers
Interventions: Temporal Interference (TI) Electrical Stimulation - NAcc 5 Hz TI Active, Temporal Interference (TI) Electrical Stimulation - NAcc 5 Hz TI Sham, Temporal Interference (TI) Electrical Stimulation - NAcc 10 Hz TI Active, Temporal Interference (TI) Electrical Stimulation - NAcc 10 Hz TI Sham; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Developmental Language Disorder, Language Impairment
Interventions: Sentence recast; Behavioral
Lead sponsor: University of Houston; Other
Eligibility: 4 Years to 6 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypovitaminosis D
Interventions: Standing Phototherapy Kiosk, D3 Oral supplement; Device · Dietary Supplement
Lead sponsor: Madigan Army Medical Center; Federal
Eligibility: 18 Years to 69 Years
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Depression in Adolescence, Rumination
Interventions: Mindfulness + fMRI Neurofeedback; Other
Lead sponsor: Columbia University; Other
Eligibility: 13 Years to 18 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Obesity
Interventions: Fit and Fab; Behavioral
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Scleroderma, Systemic, Interstitial Lung Disease
Interventions: Pirfenidone (PFD), Placebo (Plac), Mycophenolate Mofetil (MMF); Drug
Lead sponsor: Michael Roth; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 16
States / cities: Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 12 more

Conditions: Chemotherapy-induced Peripheral Neuropathy
Interventions: Arm 1: Investigational INF, Arm 2: standardized muscle stretching and strength; Other
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL)
Interventions: AZD4512 monotherapy; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Duarte, California • Jacksonville, Florida • Chicago, Illinois + 3 more

Conditions: Renal Vascular Disease, Nutcracker Syndrome, Renal, Pelvic Trauma, Loin Pain-Hematuria Syndrome, Renal Tumor, Congestion, Venous
Interventions: Pre-Operative Information, Intra-Operative Data, Post-Operative Data (up to discharge), Short-Term Follow-Up Data; Procedure · Other
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Autism Spectrum Disorder, Language Disorders
Interventions: Levoleucovorin Calcium, Placebo; Drug · Other
Lead sponsor: Southwest Autism Research & Resource Center; Other
Eligibility: 30 Months to 60 Months
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Phoenix, Arizona • Brooklyn, New York

Conditions: Speech Sound Disorder
Interventions: Traditional Therapy, Hybrid therapy; Behavioral
Lead sponsor: Syracuse University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplantation Infection, Transplantation, Bone Marrow
Interventions: Melphalan, Fludarabine, Mycophenolate mofetil, Tacrolimus, Cord Blood Infusion, Rituximab, ATG, Busulfan, Clofarabine, Total Body Irradiation (TBI); Drug · Procedure · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 1 Year to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Heart Failure
Interventions: Level 1: (provide site-specifi information), Level 2 (Provide site- and patient-specific information); Other
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Hines, Illinois

Conditions: Advanced Cancer, Metastatic Solid Tumor
Interventions: BC3195; Drug
Lead sponsor: Biocity Biopharmaceutics Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Glioblastoma, Cancer of Brain and Nervous System, Glioblastoma Multiforme
Interventions: Temozolomide, Stereotactic Radiosurgery (SRS); Drug · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Glioma, Glioblastoma, Recurrent Glioma, Recurrent Glioblastoma, Grade 4 Malignant Glioma of Brain (Disorder)
Interventions: Sitagliptin, Bevacizumab; Drug · Biological
Lead sponsor: Kailin Yang, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Postoperative Care
Interventions: capnostream 20, Oridian Medical 1987 ltd, Needham MA; Device
Lead sponsor: Allenmore Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Autism Spectrum Disorder, Psychosis, Social Communication
Interventions: PEERS social skills intervention; Behavioral
Lead sponsor: Loma Linda University; Other
Eligibility: 12 Years to 18 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Osteoarthritis, Hip, Joint Deformities, Acquired, Hip Dislocation, Congenital, Osteonecrosis, Arthritis, Rheumatoid
Interventions: Aquamantys, standard electrocautery (Bovie); Device
Lead sponsor: Joint Implant Surgeons, Inc.; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New Albany, Ohio

Conditions: Breast Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Thoracic Cancer, Genitourinary Cancer
Interventions: Clinician Nudge Email, Patient Nudge Letter and Share questionaire; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: B-cell Non-Hodgkin Lymphoma
Interventions: AZD4512, Surovatamig; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 8
States / cities: Irvine, California • Jacksonville, Florida • Rochester, Minnesota + 4 more

Conditions: High Grade Anal Canal Squamous Intraepithelial Neoplasia, HIV Infection
Interventions: Concept Elicitation, Comprehension Assessment; Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 35 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: San Francisco, California • Chicago, Illinois • New York, New York + 1 more

Search by objective public record fields.

Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Clinical Effectiveness of Body Fat Distribution Imaging in Real-World Practice: The BODY-REAL Study

Temporal Interference Methods for Non-invasive Deep Brain Stimulation, Study 1.2

The Relationship Between Child Language Proficiency and Language of Treatment on the Outcomes of Bilingual Children with Developmental Language Disorder

Comparing a Novel Phototherapy Kiosk to Oral Vitamin D Supplementation

Mindfulness-Based fMRI Neurofeedback for Depression

Increasing Exercise Enjoyment and Outcome Expectations Among Women With Obesity

Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate

Chemotherapy Induced Peripheral Neuropathy (CIPN)

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

Renal Autotransplantation; Case Series

Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism

Evaluating the Effectiveness of Hybrid and Traditional Speech Therapy for /ɹ/ and /s/ Sound Production

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

Beta-Blockers in Heart Failure: Pharmacy-level Intervention Comparison

A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer

Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform

Sitagliptin in Recurrent/Progressive Grade 4 Glioma

The Comparison of Pulse Oximetry, End-tidal Capnometry, and Integrated Pulmonary Index (IPI)

Neural Basis of Social Cognition Deficits

Efficacy of Aquamantys for Reducing Transfusions With Anterior Supine Intermuscular Approach Total Hip Arthroplasty

Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Health-Related Symptom Questionnaires in Measuring Quality of Life in HIV-Infected Participants Treated or Monitored for Anal Lesions